HOME >> MEDICINE >> NEWS
Studies suggest investigational agent reduces disease activity in MS

BOSTON A new drug under investigation shows a reduction in disease activity in multiple sclerosis (MS), according to two studies that will be presented at the American Academy of Neurology's 59th Annual Meeting in Boston, April 28 May 5, 2007. The drug reduced disease activity as indicated by MRI scans.

Both of the studies involved people with the relapsing-remitting form of MS, where symptoms flare up and then subside. By 24 weeks, treatment with the drug rituximab reduced the number of areas of brain damage, or lesions, in people with MS and the number of relapses, or times when symptoms flare up, when compared with placebo.

Rituximab is a therapeutic antibody that selectively targets and depletes a subset of immune cells called B-cells by targeting a specific protein on their surface.

"This is the first drug to target B-cells and may represent a potential new treatment strategy for relapsing-remitting MS," said study author Stephen Hauser, MD, of the University of California, San Francisco, and a member of the American Academy of Neurology. "While these are early stage clinical trials, these results are exciting, because the current drugs available for MS are only partially effective in reducing disease activity and preventing exacerbations. New and more effective treatments for MS are sorely needed, especially for people who do not adequately respond to currently available medications. These data are also important because they demonstrate that B-cells, which are the precursors of antibody-producing cells, play an essential role in mediating relapses of MS."

In the first study, a randomized, placebo-controlled trial, 69 people were given two infusions of rituximab two weeks apart and 35 were given a placebo. The participants were followed for six months. Those given rituximab had approximately 90 percent fewer brain lesions than those given placebo. During the six-month period, 58 percent fewer of those taking the d
'"/>

Contact: Angela Babb
ababb@aan.com
651-695-2789
American Academy of Neurology
1-May-2007


Page: 1 2 3

Related medicine news :

1. Studies show antidepressants not linked to birth defects
2. Studies show role of age, gender, race and weight on cancer risk and treatment
3. Studies highlight advances in diagnosis, medical therapy
4. Studies highlight real world use, safety of drug-eluting stents
5. Studies led by Rhode Island Hospital confirm safety and efficacy
6. Studies identify food sources of disease and drug resistance
7. Studies provide new evidence on risks associated with Cox-2 inhibitors and NSAIDs
8. Studies highlight need to monitor heart function in breast cancer patients
9. Studies examine physician disclosure of medical errors
10. Studies indicate medication can be an effective therapy for smoking cessation
11. Studies evaluating health effects of dental amalgam fillings in children confirm safety

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2018)... ... December 06, 2018 , ... The University of ... install LED light fixtures containing Indigo-Clean continuous environmental disinfection. The lights are ... the forefront of collegiate gymnastics programs across the nation by providing this new, proven ...
(Date:12/5/2018)... DALLAS, Texas (PRWEB) , ... December 05, 2018 ... ... proved its leading SkinPen Precision device is setting a new standard as the ... Aesthetics Everything win. , Each year this award is presented at the renowned ...
(Date:12/5/2018)... ... December 05, 2018 , ... ... patient and family engagement with the use of the Precision Virtual Reality® ... provides Children’s National’s world-renowned neurosurgeons and physicians with a never-before view of ...
(Date:12/5/2018)... ... December 05, 2018 , ... Marking its seventh year, ... celebration “A Toast Heard ‘Round the World” on New Year’s Eve. Each year ... global community (alumni, students, faculty members, staff, families, and friends of the institution) to ...
(Date:12/5/2018)... Ill. (PRWEB) , ... December 05, 2018 , ... ... CRO, FSP, Strategic Resourcing, and Consulting services, announced its new office location in ... will accommodate organic growth of clinical trial operations in Europe and additional in-country ...
Breaking Medicine News(10 mins):
(Date:12/5/2018)... ... 05, 2018 , ... NDA Partners Chairman Carl Peck, ... Laboratory Integration at the United States Pharmacopeial Convention (USP), has joined the firm ... experience in domestic and international operations harmonization, compendial affairs, and the development and ...
(Date:11/29/2018)... Fla. (PRWEB) , ... November 29, 2018 , ... ... practitioner-channel dietary supplement company – announced today the launch of the Annatto-E™ product ... annatto plant (Bixa orellana). Backed by clinical research, DFH’s new Annatto-E™ products are ...
(Date:11/29/2018)... ... ... Windsor Gardens Healthcare Center of the Valley (“Windsor Gardens”), a skilled ... selected by the California Association of Health Facilities (CAHF) as only one of 20 ... California Department of Public Health awarded a grant of $700,000 to CAHF to develop ...
Breaking Medicine Technology:
Cached News: